Patents Examined by Sumesh Kaushal
  • Patent number: 8298816
    Abstract: Promoter activities were examined by comparing combinations of promoters and enhancers derived from various genes. A hybrid promoter comprising a combination of a CMV enhancer and a mammalian ?-actin promoter, or the post-transcriptional regulatory region of the genomic sequence Woodchuck Hepatitis Virus (WPRE) and a mammalian ?-actin promoter was found to be stronger than existing promoters. Furthermore, the activities of the ?-actin promoters could be enhanced by coexpressing the oncogene product Ras, which is a transactivator.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: October 30, 2012
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Tsunoda, Kiyoshi Habu
  • Patent number: 8282915
    Abstract: Delivery systems and methods are provided for delivering a biologically active protein to a host animal. The systems and methods provided include obtaining an algal cell transformed by an expression vector, the expression vector comprising a nucleotide sequence coding for the biologically active protein, operably linked to a promoter. In one illustrated embodiment, the biologically active protein is an antigenic epitope and upon administration to the animal the algal cell induces an immune response in the host animal.
    Type: Grant
    Filed: June 24, 2008
    Date of Patent: October 9, 2012
    Assignees: Phyterra Bio Inc., The Ohio State University
    Inventors: Richard T. Sayre, Richard E. Wagner, Surasak Siripornadulsil, Carlos Farias
  • Patent number: 8263398
    Abstract: The invention constructs an activating KRASmutant but not p53-responsive promoter and generates an E1B-55kD-deleted (?E1B-55kD) adenovirus, harboring a transcriptionally activating transgene and holding lytic replication ability in the tumor cells with activating KRASmutant. The adenovirus of the invention can be used in the treatment of cancers.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: September 11, 2012
    Inventors: Jin-Hwang Liu, Chin-Cheng Liu
  • Patent number: 8263821
    Abstract: The invention relates to a method for optical detection of the dynamics of Ca2+ in a biological system, said method comprising monitoring the photons emitted by a recombinant Ca2+-sensitive polypeptide, which comprises or consists of a chemiluminescent protein linked to a fluorescent protein, present in said biological system. In a particular embodiment, said recombinant polypeptide comprises or consists of the Aequorin and GFP linked by a linker allowing chemiluminescence resonance energy transfer (CRET), and optionally comprises a peptidic fragment capable of targeting said recombinant polypeptide into a specific cellular domain or compartment. The present invention also concerns a transgenic non-human animal expressing said recombinant polypeptide sensitive to calcium concentration, in conditions enabling the in vivo monitoring of Ca2+ dynamics.
    Type: Grant
    Filed: January 11, 2005
    Date of Patent: September 11, 2012
    Assignee: Institut Pasteur
    Inventors: Philippe Brulet, Kelly Rogers, Sandrine Picaud
  • Patent number: 8236294
    Abstract: Methods and compositions are presented for the administration of transposon-based vectors to an animal or human to provide gene therapy to the animal or human.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: August 7, 2012
    Assignees: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, TransGenRx, Inc.
    Inventors: Richard K. Cooper, Frederick M. Enright, William C. Fioretti
  • Patent number: 8227661
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO227, PRO233, PRO238, PRO1328, PRO4342, PRO7423, PRO10096, PRO21384, PRO353 or PRO1885 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: July 24, 2012
    Assignee: Lexicon Genetics, Inc.
    Inventors: Joel A. Edwards, Wenhu Huang, Charles Montgomery, Ni Nancy Qian, Zheng-Zheng Shi, Mary Jean Sparks, Peter Vogel, Mindy Oox
  • Patent number: 8222225
    Abstract: Methods are disclosed for treating, preventing or reducing the risk of developing occupational lung diseases, such as pneumoconiosis. In several embodiments, the methods include administering a therapeutically effective amount of the suppressive ODN to a subject having or at risk of developing a pneumoconiosis, thereby treating or inhibiting the pneumoconiosis. In several examples, thee subject can have or be at risk of developing silicosis, asbestosis or berryliosis. The method can include selecting a subject exposed to, or at risk of exposure to, inorganic particles, including, but not limited to silica, asbestos, berrylium, coal dust, or bauxite.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: July 17, 2012
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dennis M. Klinman, Takashi Sato
  • Patent number: 8211421
    Abstract: The invention concerns a polypeptide having a uracil phosphoribosyl transferase (UPRTase) by mutation of one or several residues of the UPRTase. The invention also concerns a nucleotide sequence coding for the UPRTase mutant, a vector for expressing the latter, a viral particle, a host cell, and a composition containing them. The invention further concerns their therapeutic use and a treatment method using them. The invention is particularly useful in the context of therapy by suicide genes, in particular, for treating proliferative and infectious diseases.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: July 3, 2012
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Richard Jund
  • Patent number: 8207141
    Abstract: DNA plasmids containing sequences coding for different fragments of 185neu oncoprotein which are able to induce an immune response against p185neu-overexpressing tumors, and pharmaceutical compositions thereof are described.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: June 26, 2012
    Inventors: Augusto Amici, Cristina Marchini, Elena Quaglino, Federica Cavallo, Guido Forni
  • Patent number: 8193408
    Abstract: The invention relates to nematodes as model organisms for the investigation of neurodegenerative diseases, in particular, Parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene, From C elegans, which is homologous to the human parkin gene associated with Parkinsons disease. The invention further relates to those nematodes which contain an aberrant or missing expression of at least one gene, preferably a parkin gene and/or a ?-synucleine gene, which is connected with Parkinsons disease. According to the invention, the above organisms can be used for the identification and characterization of medicaments for the treatment of said disease states.
    Type: Grant
    Filed: June 3, 2008
    Date of Patent: June 5, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Marius Hoener, Giuseppe Cassata, Wolfgang Link, Ralf Baumeister, Karlheiniz Tovar
  • Patent number: 8153119
    Abstract: The present invention is directed to engineered enzymatically active bacteriophages that are both capable of killing the bacteria by lysis and dispersing the bacterial biofilm because they have been also engineered to express biofilm-degrading enzymes, particularly dispersin B (DspB), an enzyme that hydrolyzes ?-1,6-N-acetyl-D-glucosamine, a crucial adhesion molecule needed for biofilm formation and integrity in Staphylococcus and E. coli, including E. coli K-12, as well as clinical isolates.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: April 10, 2012
    Assignees: Trustees of Boston University, Massachusetts Institute of Technology
    Inventors: James J Collins, Timothy Kuan-Ta Lu
  • Patent number: 8124592
    Abstract: The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: February 28, 2012
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Gary J. Nabel, Zhi-yong Yang, Nancy Sullivan, Anthony Sanchez
  • Patent number: 8106027
    Abstract: The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: January 31, 2012
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Gary J. Nabel, Zhi-yong Yang, Nancy Sullivan, Anthony Sanchez
  • Patent number: 8106026
    Abstract: The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: January 31, 2012
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Gary J. Nabel, Zhi-yong Yang, Nancy Sullivan, Anthony Sanchez
  • Patent number: 8080376
    Abstract: Through screening of an expression library, a cDNA sequence has been identified that encodes a protein that interacts with human CD33, the DNA being highly homologous to a portion of the human dystrophin gene. A region of that cDNA has been identified as an important regulatory element in controlling expression, both transcription and translation, of the DNA with which it is associated. This DNA sequence element may be used as a regulatory cassette in conjunction with any suitable gene, to modify gene expression. The putative controlling DNA sequence element contains a minimum of 137 base pairs (FIG. 1) to 147 base pairs (FIG. 1A) and a maximum of 287 base pairs (FIG. 1B).
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: December 20, 2011
    Inventor: Elizabeth K. Barber
  • Patent number: 8071364
    Abstract: Methods and compositions are presented for the administration of transposon based vectors to an animal or human to provide gene therapy to the animal or human.
    Type: Grant
    Filed: December 24, 2004
    Date of Patent: December 6, 2011
    Assignees: TransGenRx, Inc., The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Richard Cooper, Frederick M. Enright, William C. Fioretti
  • Patent number: 8067666
    Abstract: A model rodent animal with a phenotype in which hair growing after birth is black, with the animal spontaneously developing white hair after aging. By way of example, the model rodent animal may have a genotype in which an activated RET gene is genetically inserted in a heterozygous form and the endothelin receptor B gene is deficient in a heterozygous form.
    Type: Grant
    Filed: February 10, 2006
    Date of Patent: November 29, 2011
    Assignee: Chubu University Educational Foundation
    Inventor: Masashi Kato
  • Patent number: 8058253
    Abstract: This invention is related to compositions and methods for decreasing cholesterol levels in a subject. The method utilizes a nucleic acid expression construct that encodes a growth-hormone-releasing-hormone (“GHRH”) that is delivered into a tissue of the subject, wherein, GHRH is expressed in vivo in the subject.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: November 15, 2011
    Assignee: VGX Pharmaceuticals, Inc.
    Inventors: Ruxandra Draghia-Akli, Amir S. Khan, Marta L. Fiorroto
  • Patent number: 8058502
    Abstract: Ubiquitin ligase wwp-1 and ubiquitin conjugating enzyme ubc-18 are identified in nematodes as mediators of dietary restriction induced longevity and therefore as targets for modulation of lifespan in animals. Methods of screening for compounds that modulate longevity by assaying wwp-1 ubiquitination pathway parameters are provided, as are related systems. In addition, methods of using wwp-1 and/or ubc-18 to modulate longevity or delay onset of age-related diseases are described.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: November 15, 2011
    Assignee: The Salk Institute for Biological Studies
    Inventors: Andrea C. Carrano, Andrew Dillin, Tony Hunter
  • Patent number: 7985407
    Abstract: The present invention provides a method of immune/gene combination therapy that has an effect of suppressing growth of an intractable solid tumor and is useful for treatment of such a tumor, and a therapeutic composition used for said method.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: July 26, 2011
    Assignee: National Cancer Center
    Inventors: Kazunori Aoki, Teruhiko Yoshida